Sanofi’s SAR445399 Lung Trial Moves Ahead: What Investors Should Watch

Sanofi SA (SNY) announced an update on their ongoing clinical study.

Sanofi (SNY) is running a mid-stage trial called “A Randomized, Double-blinded, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Activity, Safety, and Tolerability of SAR445399 in Adult Participants With Non-Cystic Fibrosis Bronchiectasis (NCFB).” The study aims to see if SAR445399 can safely cut mucus build-up in damaged airways, a key driver of symptoms and flare-ups in these chronic lung patients.

The main treatment is SAR445399, a lab-made biologic drug given as an injection. It is designed to reduce mucus plugging in the lungs and improve breathing compared with a matching placebo injection.

The trial is interventional and randomized, so participants are split by chance into groups. It uses a parallel design, with some patients getting SAR445399 and others getting placebo, and neither patients nor study staff know who gets which, to keep the results unbiased.

The study’s primary goal is treatment focused, looking at changes in mucus plug score after 24 weeks. Safety and tolerability are tracked in both groups to see if the drug’s benefits outweigh its risks for adults aged 18 to 80 with non‑cystic fibrosis bronchiectasis.

The trial started enrollment after first submission on April 17, 2026, and is now listed as recruiting. The latest protocol update was filed on May 12, 2026, signaling active study management and ongoing site activation.

Primary completion will come once enough patients finish the 24‑week treatment period, which will be the first major readout for efficacy. Final completion will follow later, once all follow‑up is done and full safety data are gathered for regulatory and strategic decisions.

For investors, this update adds another late early-stage asset to Sanofi’s respiratory pipeline, in a niche with limited approved options. Progress in bronchiectasis could support a growth story beyond traditional asthma and COPD drugs, if the data show clear benefits.

Competitors like AstraZeneca, GSK, and smaller biotechs are also working on chronic lung disease and inflammation. A positive signal here could lift sentiment toward SNY’s innovation profile, while weak or unclear results might push investors toward peers with more advanced respiratory assets.

Since the trial is only Phase 2a, any impact on near-term revenue is distant and risk remains high. However, steady recruiting and recent updates on ClinicalTrials.gov should reassure investors that the program is active, with ongoing work and further details available on the ClinicalTrials portal.

To learn more about SNY’s potential, visit the Sanofi SA drug pipeline page.